Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients

Aktuelle Urologie

Volumn 50, Issue 3, 2019, Pages 292-297

  Chen, Hong Ray ^a   Kao, Chien Chang ^a   Tsao, Chih Wei ^a   Tang, Shou Hung ^a   En, Meng ^a   Cha, Tai Lung ^a   Sun, Guang Huan ^a   Wu, Seng Tang ^a   Yu, Dah Shyong ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

bladder; high risk; intravesical instillation; Mitomycin C; urothelial cell carcinoma

Indexed keywords

MITOMYCIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BLADDER TUMOR; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREVENTION AND CONTROL; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 85069794928     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/a-0750-5595     Document Type: Article

References (27)

1. Burger M. Catto J. W. Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol: 2013; 63 234 241
2. GLOBOCAN Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx Published 2012
3. Ploeg M. Aben K. KH. Kiemeney L. A. The present and future burden of urinary bladder cancer in the world. World J Urol: 2009; 27 289 293
4. Vaidya A. Soloway M. S. Hawke C. et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol: 2001; 165 47 50
5. Jancke G. Rosell J. Jahnson S. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. Scand J Urol: 2014; 48 276 283
6. Steinmaus C. Ferreccio C. Acevedo J. et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomarkers Prev: 2014; 23 1529 1538
7. Colombo R. Naspro R. Bellinzoni P. et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag: 2007; 3 1003 1007
8. Chavan S. Bray F. Lortet-Tieulent J. et al. International variations in bladder cancer incidence and mortality. Eur Urol: 2014; 66 59 73
9. Malmström P-U. Sylvester R. J. Crawford D. E. et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol: 2009; 56 247 256
10. Mostafid A. H. Palou Redorta J. Sylvester R. et al. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol: 2015; 67 359 360
11. Veeratterapillay R. Heer R. Johnson M. I. et al. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep: 2016; 17 68
12. Sylvester R. J. Oosterlinck W. Witjes J. A. The Schedule and Duration of Intravesical Chemotherapy in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials. Eur Urol: 2008; 53 709 719
13. Huland H. Otto U. Droese M. et al. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence on recurrence, progression and survival. J Urol: 1984; 132 27 29
14. Badalament R. A. Farah R. N. Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol: 1997; 13 335 341
15. National Comprehensive Cancer Network Bladder cancer. Version 2.2017 https://www.nccn.org/professionals/physician-gls/pdf/bladder.pdf Accessed February 15, 2017.
16. Babjuk M. Böhle A. Burger M. et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol: 2017; 71 447 461
17. Sylvestera R. J. Oosterlinckb W. Witjesc J. A. schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol: 2008; 53 709
18. Lamm D. L. Carcinoma in situ. Urol Clin North Am: 1992; 19 499 508
19. Losa A. Hurle R. Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol: 2000; 163 68 71
20. Griffiths T. R. Charlton M. Neal D. E. et al. Treatment of carcinoma in situ with intravesical bacillus calmette-guerin without maintenance. J Urol: 2002; 167 2408 2412
21. Sylvester R. J. van der Meijden A. P. Witjes J. A. et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol: 2005; 174 86 91
22. Sylvester R. J. van der Meijden A. P. Lamm D. L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol: 2002; 168 1964 1970
23. Kutwin P. Konecki T. Cichocki M. et al. Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review. Photomed Laser Surg: 2017; 35 459 464
24. Malmström P. U. Sylvester R. J. Crawford D. E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol: 2009; 56 247 256
25. Dalbagni G. Vora K. Kaag M. et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol: 2009; 56 903 910
26. Bishr M. Lattouf J-B. Latour M. et al. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J: 2014; 8 E306 E310
27. Au J. L. Badalament R. A. Wientjes M. G. et al. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst: 2001; 93 597 604